| Symbol | Name | Last Close | Mkt Cap | DailyStocks' Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
|
Vote Now! Monday’s Close |
|---|---|---|---|---|---|
| GSK | GlaxoSmithKline PLC | $39.21 | $97.25B | Sell |
Merck's Keytruda Gets Nod for First-Line Lung Cancer in China
http://www.zacks.com/stock/news/369336/mercks-keytruda-gets-nod-for-first-line-lung-cancer-in-china?cid=CS-ZC-FT-369336
Apr 02, 2019 - Merck's (MRK) Keytruda receives approval for treating nonsquamous non-small cell lung cancer in combination with chemotherapies in first-line setting in China.
0
Top Analyst Reports for Chevron, IBM & Medtronic
http://www.zacks.com/research-daily/368238/top-analyst-reports-for-chevron-ibm-medtronic?cid=CS-ZC-FT-368238
Apr 01, 2019 - Top Analyst Reports for Chevron, IBM & Medtronic
0
3 Big Pharma Stocks to Add to Your Portfolio This April
http://www.zacks.com/stock/news/368171/3-big-pharma-stocks-to-add-to-your-portfolio-this-april?cid=CS-ZC-FT-368171
Apr 01, 2019 - The large-cap pharma industry is on a strong footing in 2019. Here are three stocks from the space that investors may consider betting on.
0
GSK Prescribes A $3.5bn Bond In 3 Parts
https://seekingalpha.com/article/4250143-gsk-prescribes-3_5bn-bond-3-parts?source=feed_all_articles
Mar 21, 2019 - British pharma giant GlaxoSmithKline joined the recent groundswell of high-grade corporate bond issuers Monday to sell new debt.The UK-based firm priced US$3.5bn worth of ‘A’-rated, three-, five- and
0
Emergent Begins Phase III Study on Anthrax Vaccine AV7909
http://www.zacks.com/stock/news/362304/emergent-begins-phase-iii-study-on-anthrax-vaccine-av7909?cid=CS-ZC-FT-362304
Mar 20, 2019 - Emergent (EBS) kicks off a late-stage study on its investigational anthrax vaccine AV7909.
0
Glaxo Presents Encouraging Data on Endometrial Cancer Drug
http://www.zacks.com/stock/news/362265/glaxo-presents-encouraging-data-on-endometrial-cancer-drug?cid=CS-ZC-FT-362265
Mar 20, 2019 - Glaxo (GSK) presents encouraging data from phase I/II study on endometrial cancer drug, dostarlimab.
0
Novartis' (NVS) Alcon Acquired PowerVision for $285 Million
http://www.zacks.com/stock/news/360866/novartis-nvs-alcon-acquired-powervision-for-%24285-million?cid=CS-ZC-FT-360866
Mar 18, 2019 - Novartis' (NVS) eye-care unit, Alcon acquires PowerVision to drive growth in advanced technology intraocular lenses (AT-IOLS) for cataract surgery patients.
0
Gilead Reports Positive Data on HIV Drugs Biktarvy & Descovy
http://www.zacks.com/stock/news/358436/gilead-reports-positive-data-on-hiv-drugs-biktarvy-descovy?cid=CS-ZC-FT-358436
Mar 08, 2019 - Gilead (GILD) presents encouraging data on two leading HIV regimens, Bikatrvy and Descovy.
0
Top Research Reports for Microsoft, Mastercard & General Electric
http://www.zacks.com/research-daily/228770/top-research-reports-for-microsoft-mastercard-general-electric?cid=CS-ZC-FT-228770
Mar 08, 2019 - Top Research Reports for Microsoft, Mastercard & General Electric
0
Gilead Reports Positive Data on HIV Drugs Biktarvy & Descovy
http://www.zacks.com/stock/news/358194/gilead-reports-positive-data-on-hiv-drugs-biktarvy-descovy?cid=CS-ZC-FT-358194
Mar 07, 2019 - Gilead (GILD) presents encouraging data on two leading HIV regimens, Bikatrvy and Descovy.
0